Discontinued — last reported Q4 '23
Cardiovascular — Operating Income (Loss) Allocated to Reportable Segments
Boston Scientific Cardiovascular — Operating Income (Loss) Allocated to Reportable Segments remained flat by 0.0% to $558.75M in Q4 2023 compared to the prior quarter. Year-over-year, this metric grew by 5.8%, from $528.25M to $558.75M. Over 2 years (FY 2021 to FY 2023), Cardiovascular — Operating Income (Loss) Allocated to Reportable Segments shows an upward trend with a 24.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates improved operational efficiency, better pricing power, or successful cost management within the Cardiovascular product lines. A decrease may signal rising production costs, increased competitive pressure, or higher investment requirements that are outpacing revenue growth.
Detailed definition
This metric represents the profitability of the Cardiovascular business segment after accounting for direct costs and al...
Peer comparison
Comparable to segment-level operating income reported by other diversified medical device manufacturers, often evaluated alongside segment margins to normalize for size differences.
bsx_segment_cardiovascular_operating_income_loss_allocated_to_reportable_segmentsHistorical Data
| FY'21 | FY'22 | FY'23 | |
|---|---|---|---|
| Value | $1.45B | $2.11B | $2.24B |
| YoY Change | — | +45.9% | +5.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Boston Scientific's cardiovascular — operating income (loss) allocated to reportable segments?
- Boston Scientific (BSX) reported cardiovascular — operating income (loss) allocated to reportable segments of $558.75M in Q4 2023.
- How has Boston Scientific's cardiovascular — operating income (loss) allocated to reportable segments changed year-over-year?
- Boston Scientific's cardiovascular — operating income (loss) allocated to reportable segments increased by 5.8% year-over-year, from $528.25M to $558.75M.
- What is the long-term trend for Boston Scientific's cardiovascular — operating income (loss) allocated to reportable segments?
- Over 2 years (2021 to 2023), Boston Scientific's cardiovascular — operating income (loss) allocated to reportable segments has grown at a 24.2% compound annual growth rate (CAGR), from $1.45B to $2.24B.
- What does cardiovascular — operating income (loss) allocated to reportable segments mean?
- The operating profit generated specifically by the Cardiovascular business segment.